|
|
|
|
| LEADER |
02595nam a2200337 u 4500 |
| 001 |
EB001888817 |
| 003 |
EBX01000000000000001052178 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
200106 r ||| eng |
| 245 |
0 |
0 |
|a Clinical review report: Ertugliflozin (Steglatro) (Merck Canada Inc.)
|h Elektronische Ressource
|b indication : type 2 diabetes mellitus
|
| 246 |
3 |
1 |
|a Ertugliflozin (Steglatro) (Merck Canada Inc.)
|
| 246 |
3 |
1 |
|a Clinical review report for Steglatro
|
| 250 |
|
|
|a Final (with redactions)
|
| 260 |
|
|
|a Ottawa (ON)
|b CADTH
|c February 2019, 2019
|
| 300 |
|
|
|a 1 PDF file (111 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Canada
|
| 653 |
|
|
|a Sodium-Glucose Transporter 2 Inhibitors / therapeutic use
|
| 653 |
|
|
|a Sodium-Glucose Transporter 2 Inhibitors / adverse effects
|
| 653 |
|
|
|a Diabetes Mellitus, Type 2 / drug therapy
|
| 653 |
|
|
|a Treatment Outcome
|
| 653 |
|
|
|a Bridged Bicyclo Compounds, Heterocyclic / therapeutic use
|
| 653 |
|
|
|a Bridged Bicyclo Compounds, Heterocyclic / adverse effects
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH common drug review
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK542486
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a Diabetes mellitus is a metabolic disease that is characterized by persistent elevations in blood glucose (hyperglycemia). This persistent elevated blood glucose causes damage to blood vessels on a microvascular (retinopathy, nephropathy, and neuropathy) and macrovascular (peripheral artery disease, cardiovascular [CV] disease) level. Diabetes is one of the most common chronic diseases in Canada. Diabetes Canada estimated that there were 3.4 million people (9.3% of the population) with diabetes in 2015, and by 2025 this number will have increased to five million people (12.1%). The objective was to perform a systematic review of the beneficial and harmful effects of ertugliflozin (ERT) 5 mg and 15 mg tablets to improve glycemic control in adult patients with type 2 diabetes mellitus for whom metformin is inappropriate due to contraindications or intolerance (as monotherapy); or in combination with metformin, or metformin and sitagliptin, when these therapies, along with diet and exercise, do not provide adequate glycemic control. This review was conducted in tandem with an evaluation of the ERT/metformin fixed-dose combination product, Segluromet
|